| 2025-10-29 |
详情>>
内部人交易：
BOUSBIB ARI等共交易11笔
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本17030.00万股
变动原因 ▼▲
- 原因：
- 20250630-20250930
发行普通股
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益4.90美元,归母净利润8.46亿美元,同比去年增长-9.62%
|
| 2025-10-28 |
财报披露：
美东时间 2025-10-28 盘前发布财报
|
| 2025-07-22 |
详情>>
业绩披露：
2025年中报每股收益2.96美元,归母净利润5.15亿美元,同比去年增长-20.89%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益1.42美元,归母净利润2.49亿美元,同比去年增长-13.54%
|
| 2025-02-28 |
股东大会：
将于2025-04-24召开股东大会
会议内容 ▼▲
- 1.Annual election of the director nominees named in the accompanying Proxy Statement
2.Advisory (nonbinding) vote to approve our executive compensation (sayonpay)
3.Ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025
4.Approve an amendment to our Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation
5.Stockholder proposal, if properly presented
|
| 2025-02-13 |
详情>>
业绩披露：
2022年年报每股收益5.82美元,归母净利润10.91亿美元,同比去年增长12.94%
|
| 2025-02-13 |
详情>>
业绩披露：
2024年年报每股收益7.57美元,归母净利润13.73亿美元,同比去年增长1.10%
|
| 2024-10-31 |
详情>>
业绩披露：
2024年三季报(累计)每股收益5.14美元,归母净利润9.36亿美元,同比去年增长5.29%
|
| 2024-07-22 |
详情>>
业绩披露：
2023年中报每股收益3.17美元,归母净利润5.86亿美元,同比去年增长0.86%
|
| 2024-07-22 |
详情>>
业绩披露：
2024年中报每股收益3.58美元,归母净利润6.51亿美元,同比去年增长11.09%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益1.58美元,归母净利润2.88亿美元,同比去年增长-0.35%
|
| 2024-02-23 |
股东大会：
将于2024-04-16召开股东大会
会议内容 ▼▲
- 1.Election of six director nominees to one-year terms
2.Approve an advisory (non-binding) resolution to approve our executive compensation (say-on-pay)
3.Consider a stockholder proposal, if properly presented
4.Ratify our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024
5.Other business, if properly raised.
|
| 2024-02-15 |
详情>>
业绩披露：
2023年年报每股收益7.39美元,归母净利润13.58亿美元,同比去年增长24.47%
|
| 2023-11-01 |
详情>>
业绩披露：
2023年三季报(累计)每股收益4.82美元,归母净利润8.89亿美元,同比去年增长2.89%
|
| 2023-02-27 |
股东大会：
将于2023-04-18召开股东大会
会议内容 ▼▲
- 1.Election of three director nominees to one-year terms
2.Approve an advisory (non-binding) resolution to approve our executive compensation (say-on-pay)
3.Approve an amendment to our Certificate of Incorporation to adopt a stockholders’ right to request a special stockholder meeting
4.Consider a stockholder proposal, if properly presented, concerning special stockholder meetings
5.Consider a stockholder proposal, if properly presented, for separate Chairman and Chief Executive Officer roles
6.Ratify our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2023
|
| 2022-02-28 |
股东大会：
将于2022-04-12召开股东大会
会议内容 ▼▲
- 1.Elect the four Class III director nominees named in the accompanying Proxy Statement for a three-year term
2.Approve our Amended and Restated Certificate of Incorporation to declassify the Board of Directors over time and provide for the annual election of all directors
3.Approve an advisory (non-binding) resolution to approve executive compensation (say-on-pay)
4.Consider a stockholder proposal, if properly presented
5.Ratify our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-02-26 |
股东大会：
将于2021-04-13召开股东大会
会议内容 ▼▲
- 1.Election of three Class II director nominees named in the accompanying Proxy Statement for a three-year term
2.Advisory (non-binding) vote on the frequency of future stockholder advisory votes to approve executive compensation
3.Amendment of IQVIA Holdings Inc.’s Amended and Restated Certificate of Incorporation to remove supermajority voting standards applicable to the following actions:
3.1.amending the Bylaws of the Company
3.2.removing, for cause only, a director or the entire Board of Directors from office
4.Ratification of our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2021
5.Other business, if properly raised
|
| 2020-02-18 |
股东大会：
将于2020-04-06召开股东大会
会议内容 ▼▲
- 1.Election of three Class I director nominees named in the accompanying Proxy Statement for a three-year term.
2.Advisory (non-binding) vote to approve executive compensation (say-on-pay).
3.Ratification of our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2020.
4.Other business, if properly raised.
|
| 2019-02-21 |
股东大会：
将于2019-04-09召开股东大会
会议内容 ▼▲
- 1.Election of the four Class III director nominees named in the accompanying proxy statement for a three-year term
2.Ratification of our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2019
|
| 2018-05-17 |
复牌提示：
2018-05-16 13:22:11 停牌，复牌日期 2018-05-16 15:13:01
|
| 2018-03-01 |
股东大会：
将于2018-04-10召开股东大会
会议内容 ▼▲
- 1.Election of the four nominees for Class II director named in the accompanying proxy statement for a three-year term
2.Ratification of our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2018
|
| 2017-02-22 |
股东大会：
将于2017-04-06召开股东大会
会议内容 ▼▲
- 1.Election of the four nominees for Class I director named in the accompanying proxy statement for a three-year term
2.Advisory (nonbinding) vote to approve executive compensation
3.Advisory (nonbinding) vote on the frequency of future stockholder advisory (nonbinding) votes to approve executive compensation
4.Approve the adoption of the Quintiles IMS Holdings, Inc. 2017 Incentive and Stock Award Plan
5.Ratification of our Audit Committee’s appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2017
|
| 2016-08-11 |
股东大会：
将于2016-09-22召开股东大会
会议内容 ▼▲
- 1.to consider and vote on the proposal to approve the Agreement and Plan of Merger, dated as of May 3, 2016 by and between Quintiles and IMS Health Holdings, Inc. (“IMS Health”), a Delaware corporation (the “merger agreement”), a copy of which is included as Appendix A to the joint proxy statement/prospectus of which this notice is a part, which is conditioned on the approval of the issuance of shares of common stock of Quintiles as the surviving corporation in the merger (the “Surviving Corporation”), the proposal to reincorporate Quintiles in Delaware immediately prior to the completion of the merger and the proposals regarding the Delaware certificate of incorporation
2.to consider and vote on the proposal to approve the issuance of shares of Surviving Corporation common stock to IMS Health stockholders pursuant to the merger, which is conditioned on the approval of the merger agreement, the proposal to reincorporate Quintiles in Delaware immediately prior to the completion of the merger and the proposals regarding the Delaware certificate of incorporation
3.to consider and vote on the proposal to reincorporate Quintiles in Delaware immediately prior to the completion of the merger, as described in the joint proxy statement/prospectus of which this notice is a part, which is conditioned on the approval of the merger agreement, the issuance of shares of Surviving Corporation common stock in the merger, and the proposals regarding the Surviving Corporation’s Delaware certification of incorporation
4.to consider and vote on the proposal to approve the authorized number of shares of common stock contained in the Delaware certificate of incorporation, a copy of which is included as Appendix D to the joint proxy statement/prospectus of which this notice is a part, which is conditioned on the approval of the merger agreement, the issuance of shares of Surviving Corporation common stock in the merger, the reincorporation of Quintiles in Delaware immediately prior to completion of the merger, and the proposal regarding elimination of the supermajority voting requirement to amend certain provisions of the Delaware certificate of incorporation
5.to consider and vote on the proposal to approve the elimination of the supermajority voting requirement to amend certain provisions of the Delaware certificate of incorporation, a copy of which is included as Appendix D to the joint proxy statement/prospectus of which this notice is a part, which is conditioned on the approval of the merger agreement, the issuance of shares of Surviving Corporation common stock in the merger, the reincorporation of Quintiles in Delaware immediately prior to completion of the merger, and the proposal regarding the authorized common stock contained in the Delaware certificate of incorporation
6.to consider and vote on the proposal to approve, on an advisory (non-binding) basis, specific compensatory arrangements between Quintiles and its named executive officers relating to the merger with IMS Health, as described in the joint proxy statement/prospectus of which this notice is a part
7.to consider and vote on the proposal to adjourn the Quintiles special meeting, if necessary or appropriate, to solicit additional proxies for any proposal if there are not sufficient votes to approve Quintiles Proposals Nos. 1-5
|
| 2016-03-21 |
股东大会：
将于2016-05-05召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors.
2.To hold an advisory (nonbinding) vote to approve executive compensation.
3.To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2016.
|
| 2015-03-23 |
股东大会：
将于2015-05-07召开股东大会
会议内容 ▼▲
- 1. To elect four Class II directors.
2. To hold an advisory (nonbinding) vote to approve executive compensation.
3. To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2015.
|